An HMG-CoA reductase inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mevastatin

Item No. 10010340

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2S-methyl-(1S,2,3,7S,8S,8aR)-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2-H-pyran-2-yl]ethyl]-1-naphthalenyl ester-butanoic acid
CAS Number
73573-88-3
Synonyms
  • Compactin
  • CS 500
  • L-637,312
  • ML 236B
  • NSC 281245
  • Statin I
Molecular Formula
C23H34O5
Formula Weight
390.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlEthanol: 5 mg/mlEthanol:PBS (pH 7.2) (1:1): 0.5 mg/ml
λmax
236 nm
SMILES
CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)C12
InChi Code
InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22?/m0/s1
InChi Key
AJLFOPYRIVGYMJ-DRHLORRRSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $36

    Add

    25 mg

    $70

    Add

    50 mg

    $86

    Add

    100 mg

    $120

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Mevastatin is a competitive HMG-CoA reductase inhibitor (Ki = 0.1 µM).1 In vivo, mevastatin (50 mg/kg) inhibits cholesterogenesis in the liver and ileum of normolipidemic rats, as well as enhances suppression of cholesterogenesis in cholesterol-fed rats or rats administered cholestyramine.2 Mevastatin also suppresses TNF-induced NF-κB activation (IC50 = ~17 µM) and potentiates apoptosis in human myeloid leukemia cells.3 It also suppresses induced ferroptosis in HT-1080 cells.4 Formulations containing mevastatin have been used in the treatment of familial hypercholesterolemia.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Endo, A., Kuroda, M., and Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72(2), 323-326 (1976).

    2. Fears, R., Richards, D.H., and Ferres, H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis. 35(4), 439-449 (1980).

    3. Ahn, K.S., Sethi, G., and Aggarwal, B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway. Biochem. Pharmacol. 75(4), 907-913 (2008).

    4. Conlon, M., Poltorack, C.D., Forcina, G.C., et al. A compendium of kinetic modulatory profiles identifies ferroptosis regulators. Nat. Chem. Biol. (2021).

    5. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33(11), 1569-1582 (1992).